European Biopharmaceutical Review |
 |
|
|
|
|
 |
| |
|
|
|
|
Incentivising R&D
Patent versus Patient
Nick Beckett of CMS Cameron McKenna examines the complex interface of intellectual property and competition law, and weighs up these very different approaches to stimulating innovation in the biotech sector.
|
|
|
Spotlight
Open Innovation
Thomas Bombelles of the World Intellectual
Property Organization presents the initiatives coordinated by the
consortium WIPO Re:Search in their attempt to promote research into
neglected tropical diseases through shared intellectual property. |
|
|
Identity Trust
Sign on the Digital Line
Being able to reliably identify a
digital contact is essential to business in the current global market. Mollie Shields-Uehling of SAFE-BioPharma Association examines an
industry-wide approach designed to build this trust. |
|
|
|
Monoclonal Antibodies
Hitting the Target
Zhengbin (Bing) Yao of MedImmune takes a look at the advantages of mAb therapy to respiratory,
infl ammatory and autoimmune (RIA) diseases, and reviews some key early
mAb entrants into the RIA market. |
|
|
Targeted Cancer Therapeutics
Resisting Mutation, Restricting Resistance
William C Shakespeare of ARIAD Pharmaceuticals, Inc explores the
mechanisms of resistance and next-generation agents in development for
biomarker-driven, targeted non-small cell lung cancer therapeutics,
several of which are designed specifically to target disease-resistant
mutations. |
|
|
Biological Wound Care
A Topical Subject
Wound care is a growing
business; competition is on the rise and differentiation will be the key
to success. The future, argues Paul Titley of Aesica, lies in
biologics, gene therapy and specific cell-based therapies for molecular
and genomic deficiencies. |
|
|
|
|
MRI
A Secret Weapon
Recent developments in magnetic resonance imaging
that have unlocked stronger field strengths and increased sensitivity. Ross McLennan at Brains Unlimited explores how this technology can
enhance our understanding of the disease and aid target identification. |
|
|
Digital Pathology
Picture Perfect
Digital pathology has emerged as a
core technology for drug discovery and the development of new tissue
diagnostic tests. Peter Hamilton of PathXL Ltd examines just how this
technology can offer improved efficiency, workflow and
interoperability. |
|
|
Sample Management
A Store Point
High-quality samples are an invaluable
asset for biomarker discovery and drug development. Kristina Robson of
BioStorage Technologies illustrates how samples can be handled and
stored with good storage practices to ensure their integrity is
maintained for current and future research. |
|
|
Paperless Labs
In with the New
The demand for paperless labs to bring
together isolated silos of information and establish new found
efficiencies has never been greater. Susan Najjar of Thermo Fisher
Scientific considers the factors to bear in mind when selecting a
system. |
|
|
|
|
Drug Induced Liver Injury
Mindful Medical Monitoring
Akhil Kumar, Maxim Kosov, Marcelo Yantorno and Maxim Belotserkovsky at PSI CRO AG explore the complex subject of drug induced liver injury and the impact of false diagnoses on clinical trials.
|
|
|
|
Biomanufacturing: Prophages
The Good, the Bad and the Ugly
When considering lysogenic bacteria as a host in biomanufacturing, it is essential to maintain a high degree of care during construction of the production process and ensure that well developed control tests and procedures are in place, as Marcin Los of Phage Consultants demonstrates.
|
|
|
Getting Specific
Analytical Methods: Host Cell Proteins
Olaf Stamm, Mark Jostameling, Stephanie Graze and Simone Scotti of Charles River weigh up the benefits of generic and product-specific assays for the quantitative analysis of residual host cell proteins.
|
|
|
Reinventing the Column
Analytical Methods: UHPLC
Existing analytical analysis solutions have proven inadequate for the new generation of complex protein therapeutics. Michael McGinley of Phenomenex Inc examines advances made by new UHPLC column technology that can stand up to the challenge.
|
|
|
|
|
|
